MX2021012544A - Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales. - Google Patents

Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales.

Info

Publication number
MX2021012544A
MX2021012544A MX2021012544A MX2021012544A MX2021012544A MX 2021012544 A MX2021012544 A MX 2021012544A MX 2021012544 A MX2021012544 A MX 2021012544A MX 2021012544 A MX2021012544 A MX 2021012544A MX 2021012544 A MX2021012544 A MX 2021012544A
Authority
MX
Mexico
Prior art keywords
treatment
pharmaceutical compositions
novel compounds
kidney diseases
prophylaxis
Prior art date
Application number
MX2021012544A
Other languages
English (en)
Inventor
Reginald Christophe Xavier Brys
Der Geest Ronald Van
Katja Els Conrath
Thierry Jean-Claude Marie Christophe
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2021012544A publication Critical patent/MX2021012544A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe los compuestos de acuerdo con la Fórmula I: (ver Fórmula) En donde R1 es como se define en este documento. La presente invención se refiere a compuestos, métodos para su producción, composiciones farmacéuticas que comprenden los mismos y métodos de tratamiento que usan los mismos, para la profilaxis y/o el tratamiento que pueden ser útiles en la profilaxis y/o el tratamiento de la enfermedad poliquística renal (PKD), mediante la administración del compuesto de la invención.
MX2021012544A 2019-04-24 2020-04-21 Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales. MX2021012544A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1905711.6A GB201905711D0 (en) 2019-04-24 2019-04-24 Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
PCT/EP2020/061083 WO2020216740A1 (en) 2019-04-24 2020-04-21 Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases

Publications (1)

Publication Number Publication Date
MX2021012544A true MX2021012544A (es) 2021-11-12

Family

ID=66810218

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012544A MX2021012544A (es) 2019-04-24 2020-04-21 Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales.

Country Status (14)

Country Link
US (1) US20220202802A1 (es)
EP (1) EP3958863A1 (es)
JP (1) JP2022529814A (es)
KR (1) KR20220004111A (es)
CN (1) CN113727711A (es)
AU (1) AU2020263869A1 (es)
BR (1) BR112021021117A2 (es)
CA (1) CA3137445A1 (es)
GB (1) GB201905711D0 (es)
IL (1) IL287392A (es)
MA (1) MA55752A (es)
MX (1) MX2021012544A (es)
SG (1) SG11202111739VA (es)
WO (1) WO2020216740A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
US8362031B2 (en) * 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
US8609661B2 (en) * 2009-08-10 2013-12-17 The Regents Of The University Of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
TWI633887B (zh) * 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及／或治療多囊性腎臟病之藥物
US10174012B2 (en) * 2014-11-04 2019-01-08 The University Of Kansas LKB1-AMPK activators for therapeutic use in polycystic kidney disease
CA3001094A1 (en) 2015-10-09 2017-04-13 Abbvie S.A.R.L. Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use
AU2016333856C1 (en) 2015-10-09 2021-12-09 AbbVie Global Enterprises Ltd. N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
CN108602816A (zh) * 2015-10-09 2018-09-28 艾伯维公司 用于治疗囊性纤维化的新颖化合物
JP2020525446A (ja) * 2017-06-21 2020-08-27 ザ・ジョンズ・ホプキンス・ユニバーシティ 常染色体優性多発性嚢胞腎疾患を治療するための嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子

Also Published As

Publication number Publication date
KR20220004111A (ko) 2022-01-11
BR112021021117A2 (pt) 2021-12-14
JP2022529814A (ja) 2022-06-24
CN113727711A (zh) 2021-11-30
CA3137445A1 (en) 2020-10-29
SG11202111739VA (en) 2021-11-29
US20220202802A1 (en) 2022-06-30
AU2020263869A1 (en) 2021-12-23
WO2020216740A1 (en) 2020-10-29
EP3958863A1 (en) 2022-03-02
GB201905711D0 (en) 2019-06-05
MA55752A (fr) 2022-03-02
IL287392A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
MX2022008066A (es) Compuestos triciclicos sustituidos.
PH12021551019A1 (en) Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
MX2022006475A (es) Compuestos triciclicos sustituidos.
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
CY1109970T1 (el) Παραγωγα 6-11 δικυκλικου κετολιδιου
MX2018009944A (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
MX2022014942A (es) Nuevos compuestos.
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
MX2020003863A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
AU2020231934A8 (en) Compounds useful in HIV therapy
WO2020016847A3 (en) Purification process for preparation of eribulin and intermediates thereof
MX2021002188A (es) Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2023003846A (es) Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo.
WO2023073013A8 (en) Lrrk2 inhibitors
MX2021011576A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
MX2021011574A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2022006990A (es) Forma cristalina de un derivado del acido 7h-benzo[7]anuleno-2-car boxilico.